Alexion reports positive phase 3 extension data for ULTOMIRIS in paroxysmal nocturnal hemoglobinuria
Sustained efficacy of ULTOMIRIS was observed on the co-primary endpoints of transfusion avoidance and normalization of lactate dehydrogenase (LDH) levels and the secondary endpoints of LDH level reduction